Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.

Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.

Pharmaceuticals (Basel). 2019 Oct 15;12(4). pii: E155. doi: 10.3390/ph12040155.

2.

Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation.

Yard BD, Gopal P, Bannik K, Siemeister G, Hagemann UB, Abazeed ME.

Cancer Res. 2019 Nov 1;79(21):5640-5651. doi: 10.1158/0008-5472.CAN-19-0859. Epub 2019 Aug 6.

PMID:
31387923
3.

Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.

Wickstroem K, Hagemann UB, Kristian A, Ellingsen C, Sommer A, Ellinger-Ziegelbauer H, Wirnitzer U, Hagelin EM, Larsen A, Smeets R, Bjerke RM, Karlsson J, Ryan OB, Wengner AM, Linden L, Mumberg D, Cuthbertson AS.

Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):410-422. doi: 10.1016/j.ijrobp.2019.06.2508. Epub 2019 Jun 27.

PMID:
31255687
4.

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.

Hagemann UB, Ellingsen C, Schuhmacher J, Kristian A, Mobergslien A, Cruciani V, Wickstroem K, Schatz CA, Kneip C, Golfier S, Smeets R, Uran S, Hennekes H, Karlsson J, Bjerke RM, Ryan OB, Mumberg D, Ziegelbauer K, Cuthbertson AS.

Clin Cancer Res. 2019 Aug 1;25(15):4723-4734. doi: 10.1158/1078-0432.CCR-18-3476. Epub 2019 May 7.

PMID:
31064781
5.

Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models.

Wickstroem K, Hagemann UB, Cruciani V, Wengner AM, Kristian A, Ellingsen C, Siemeister G, Bjerke RM, Karlsson J, Ryan OB, Linden L, Mumberg D, Ziegelbauer K, Cuthbertson AS.

J Nucl Med. 2019 Sep;60(9):1293-1300. doi: 10.2967/jnumed.118.223701. Epub 2019 Mar 8.

6.

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.

Quanz M, Hagemann UB, Zitzmann-Kolbe S, Stelte-Ludwig B, Golfier S, Elbi C, Mumberg D, Ziegelbauer K, Schatz CA.

Oncotarget. 2018 Sep 25;9(75):34103-34121. doi: 10.18632/oncotarget.26135. eCollection 2018 Sep 25.

7.

Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma.

Hagemann UB, Mihaylova D, Uran SR, Borrebaek J, Grant D, Bjerke RM, Karlsson J, Cuthbertson AS.

Oncotarget. 2017 Apr 7;8(34):56311-56326. doi: 10.18632/oncotarget.16910. eCollection 2017 Aug 22.

8.

A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.

Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M, Canosa M, Kulbe H, Hagemann UB, Duncan AR, Fletcher L, Wilkinson RW, Powles T, Quezada SA, Balkwill FR.

J Clin Invest. 2017 Mar 1;127(3):801-813. doi: 10.1172/JCI82976. Epub 2017 Jan 30.

9.

In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.

Hagemann UB, Wickstroem K, Wang E, Shea AO, Sponheim K, Karlsson J, Bjerke RM, Ryan OB, Cuthbertson AS.

Mol Cancer Ther. 2016 Oct;15(10):2422-2431. Epub 2016 Aug 17.

10.

Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.

Hagemann UB, Gunnarsson L, Géraudie S, Scheffler U, Griep RA, Reiersen H, Duncan AR, Kiprijanov SM.

PLoS One. 2014 Jul 31;9(7):e103776. doi: 10.1371/journal.pone.0103776. eCollection 2014.

11.

Analysis of selected and designed chimeric D- and L-α-helix assemblies.

Kükenshöner T, Hagemann UB, Wohlwend D, Räuber C, Baumann T, Keller S, Einsle O, Müller KM, Arndt KM.

Biomacromolecules. 2014 Sep 8;15(9):3296-305. doi: 10.1021/bm5006883. Epub 2014 Aug 13.

PMID:
25072521
12.

Automated functional characterization of radiolabeled antibodies: a time-resolved approach.

Wang E, Björkelund H, Mihaylova D, Hagemann UB, Karlsson J, Malmqvist M, Buijs J, Abrahmsén L, Andersson K.

Nucl Med Commun. 2014 Jul;35(7):767-76. doi: 10.1097/MNM.0000000000000117.

PMID:
24709981
13.

Role of hydrophobic and electrostatic interactions in coiled coil stability and specificity.

Mason JM, Hagemann UB, Arndt KM.

Biochemistry. 2009 Nov 3;48(43):10380-8. doi: 10.1021/bi901401e.

PMID:
19743874
14.

Selection of peptides interfering with protein-protein interaction.

Gaida A, Hagemann UB, Mattay D, Räuber C, Müller KM, Arndt KM.

Methods Mol Biol. 2009;535:263-91. doi: 10.1007/978-1-59745-557-2_16.

PMID:
19377990
15.

Selectional and mutational scope of peptides sequestering the Jun-Fos coiled-coil domain.

Hagemann UB, Mason JM, Müller KM, Arndt KM.

J Mol Biol. 2008 Aug 1;381(1):73-88. doi: 10.1016/j.jmb.2008.04.030. Epub 2008 May 17.

PMID:
18586270
16.

Improved stability of the Jun-Fos Activator Protein-1 coiled coil motif: A stopped-flow circular dichroism kinetic analysis.

Mason JM, Hagemann UB, Arndt KM.

J Biol Chem. 2007 Aug 10;282(32):23015-24. Epub 2007 May 4.

Supplemental Content

Loading ...
Support Center